Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3359609 plus pembrolizumab and platinum/5-fluorouracil versus placebo plus pembrolizumab and platinum/5-fluorouracil in first-line recurrent/metastatic head and neck squamous cell carcinoma
MOH_2021-02-11_009740Phase 3Not yet recruiting
- Sponsor
- GSK
- Start
- Sep 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing GSK3359609 combination arm with Placebo control arm (2 arms). Primary endpoint: Efficacy in the overall population and PD-L1-positive population. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
feladilimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on MOH_2021-02-11_009740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-02-11_009740.